|1.||Ienaga, Kazuharu: 3 articles (06/2014 - 07/2009)|
|2.||Yokozawa, Takako: 2 articles (01/2010 - 07/2009)|
|3.||Sohn, Mimi: 1 article (06/2014)|
|4.||Naiki, Mitsuru: 1 article (06/2014)|
|5.||Jaffa, Ayad A: 1 article (06/2014)|
|6.||Nakano, K: 1 article (10/2011)|
|7.||Ienaga, K: 1 article (10/2011)|
|8.||Hasegawa, G: 1 article (10/2011)|
|9.||Mikami, Hiroki: 1 article (07/2009)|
|1.||Chronic Kidney Failure (Chronic Renal Failure)
10/01/2011 - "The former, an intrinsic antioxidant, termed NZ-419, has been reported to prevent the progression of chronic renal failure in animal models. "
07/01/2009 - "The concentration of NZ-419 (5-hydroxy-1-methylimidazolidine-2,4-dione), an intrinsic antioxidant, has been shown to increase in the sera of animals and patients with chronic renal failure (CRF). "
07/01/2009 - "First indications demonstrating the preventive effects of NZ-419, a novel intrinsic antioxidant, on the initiation and/or progression of chronic renal failure in rats."
01/01/2010 - "The adenine-loaded rats, which were used to show the intrinsic antioxidant and creatinine (Cr) metabolite, NZ-419 (5-hydroxy-1- methylimidazolidine-2,4-dione), when taken orally, prevented the progression of chronic renal failure (CRF), were used as a model to reach the severest stage 5. In this report, we show that, by using both a tubular lesion and a glomerular lesion models (adenine-loaded and 5/6 nephrectomized rats, respectively), peroral NZ-419 might be a common tool to prevent the progression of CRF at CKD stages 3 and 4 under the condition that most rats in the control group still remained at stage 4 (0.15<GFR/GFR(0)<0.29) at the last. "
|2.||Kidney Diseases (Kidney Disease)
10/01/2011 - "We analyzed serum NZ-419 levels in diabetic and nondiabetic patients with or without Stage 3 - 5 chronic kidney disease (CKD). "
01/01/2010 - "Treatment with NZ-419 (5-Hydroxy-1-methylimidazoline-2,4-dione), a novel intrinsic antioxidant, against the progression of chronic kidney disease at stages 3 and 4 in rats."
10/01/2011 - "Serum accumulation of a creatinine oxidative metabolite (NZ-419: 5-hydroxy-1- methylhydatoin) as an intrinsic antioxidant in diabetic patients with or without chronic kidney disease."
06/01/2014 - "A creatinine metabolite, 5-hydroxy-1-methylhydantoin (HMH: NZ-419), a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. "